Results 61 to 70 of about 4,513 (159)

Antagonism of NK-1R using aprepitant suppresses inflammatory response in rheumatoid arthritis fibroblast-like synoviocytes

Artificial Cells, Nanomedicine, and Biotechnology, 2019
Chronic inflammation in fibroblast-like synoviocytes (FLSs) induced by pro-inflammatory cytokines such as TNF-α plays a key role in the pathogenesis of rheumatoid arthritis (RA). The neurokinin-1 receptor (NK-1R) is one of the G protein–coupled receptors
Xiaoping Liu, Yuelan Zhu, Wei Zheng, Tangliang Qian, Haiyu Wang, Xiujuan Hou   +5 more
doaj   +1 more source

In Vitro Evaluation of a Solid Supersaturated Self Nanoemulsifying Drug Delivery System (Super-SNEDDS) of Aprepitant for Enhanced Solubility [PDF]

, 2021
Hakan Nazlı, Burcu Mesut, Yıldız Özsoy   +2 more
openalex   +1 more source

UEG Week 2025 Poster Presentations

United European Gastroenterology Journal, Volume 13, Issue S8, Page S803-S1476, October 2025.
wiley   +1 more source

Aprepitant for Erlotinib-Induced Pruritus [PDF]

, 2010
Bruno Vincenzi, Giuseppe Tonini, Daniele Santini   +2 more
openalex   +1 more source

Emerging Role of Aprepitant in Cannabis Hyperemesis Syndrome [PDF]

, 2019
Swetha Parvataneni, Lionel Varela, Sireesha M Vemuri-Reddy, Mandy L. Maneval   +3 more
openalex   +1 more source

Herrstedt J, Muss HB, Warr DG, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy‐induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy. Cancer. 2005;104:1548–55. [PDF]

, 2006

openalex   +1 more source

Antitumor Strategies Targeting Peptidergic Systems

Encyclopedia
Peptidergic systems show promise as targets for fighting tumors. While some peptides encourage the growth and spread of tumor cells and angiogenic mechanisms, others display antitumor properties. As such, peptide ligands and receptor antagonists could be
Francisco D. Rodríguez, Rafael Coveñas
doaj   +1 more source

Abstract

JPGN Reports, Volume 6, Issue S2, Page S1-S814, September 2025.
wiley   +1 more source

Combined neurokinin-1 receptor antagonist and sorafenib is a promising approach for hepatocellular carcinoma therapy

Egyptian Liver Journal
Background HCC (Hepatocellular carcinoma) is the most common primary malignant cancer in the liver. Treatment options to incurable HCC such as sorafenib, an oral multikinase inhibitor, had numerous side effects and questionable effectiveness.
Heba E. Sedky, Yasmine N. Elwany, Eman S. El Alfy, Mona N. Elwany, Yasmin M. Nabil, Hazem F. Manna, Mohamed A. Abdelaziz, Wessam F. El Hadidy   +7 more
doaj   +1 more source

Neurokinin-1 Receptor Antagonist (Aprepitant) Suppresses HIV-1 Infection of Microglia/Macrophages

, 2008
Xu Wang, Steven D. Douglas, Song Li, Yanjian Wang, Wen‐Zhe Ho   +4 more
openalex   +1 more source